These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW. J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390 [Abstract] [Full Text] [Related]
3. A registry study of Kawasaki disease patients with coronary artery aneurysms (KIDCAR): a report on a multicenter prospective registry study three years after commencement. Koyama Y, Miura M, Kobayashi T, Hokosaki T, Suganuma E, Numano F, Furuno K, Shiono J, Ebata R, Fuse S, Fukazawa R, Mitani Y. Eur J Pediatr; 2023 Feb 15; 182(2):633-640. PubMed ID: 36434403 [Abstract] [Full Text] [Related]
6. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V. Turk J Pediatr; 2019 Feb 15; 61(5):648-656. PubMed ID: 32104995 [Abstract] [Full Text] [Related]
7. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG. Pediatrics; 2019 Jun 15; 143(6):. PubMed ID: 31048414 [Abstract] [Full Text] [Related]
8. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry. McCrindle BW, Manlhiot C, Newburger JW, Harahsheh AS, Giglia TM, Dallaire F, Friedman K, Low T, Runeckles K, Mathew M, Mackie AS, Choueiter NF, Jone PN, Kutty S, Yetman AT, Raghuveer G, Pahl E, Norozi K, McHugh KE, Li JS, De Ferranti SD, Dahdah N, International Kawasaki Disease Registry *. J Am Heart Assoc; 2020 Aug 04; 9(15):e016440. PubMed ID: 32750313 [Abstract] [Full Text] [Related]
10. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH. Arch Dis Child; 2023 Oct 04; 108(10):833-838. PubMed ID: 37258054 [Abstract] [Full Text] [Related]
11. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R. Paediatr Int Child Health; 2018 Aug 04; 38(3):209-212. PubMed ID: 29768976 [Abstract] [Full Text] [Related]
12. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin. Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S. J Pediatr; 2020 Dec 04; 227():224-230.e3. PubMed ID: 32810506 [Abstract] [Full Text] [Related]
13. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW. Arch Dis Child; 2021 Mar 04; 106(3):247-252. PubMed ID: 32943389 [Abstract] [Full Text] [Related]
15. Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease. Fabi M, Andreozzi L, Frabboni I, Dormi A, Corinaldesi E, Lami F, Cicero C, Tchana B, Francavilla R, Sprocati M, Bigucci B, Balsamo C, Valin PS, Di Fazzio G, Iughetti L, Valletta E, Marchetti F, Donti A, Lanari M. Clin Rheumatol; 2021 Apr 04; 40(4):1507-1514. PubMed ID: 32936425 [Abstract] [Full Text] [Related]
16. FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms. Uittenbogaard P, Netea SA, Tanck MWT, Geissler J, Buda P, Kowalczyk-Domagała M, Okarska-Napierała M, van Stijn D, Tacke CE, US Kawasaki Disease Genetics Consortium, Burgner DP, Shimizu C, Burns JC, Kuipers IM, Kuijpers TW, Nagelkerke SQ. Front Immunol; 2024 Apr 04; 15():1323171. PubMed ID: 39359734 [Abstract] [Full Text] [Related]
19. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P. Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139 [Abstract] [Full Text] [Related]
20. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance. Tajima M, Shiozawa Y, Kagawa J. Pediatr Cardiol; 2015 Aug 26; 36(6):1159-65. PubMed ID: 25753685 [Abstract] [Full Text] [Related] Page: [Next] [New Search]